Subcutaneous Biologics Market Growth Spurred by Accelerating Cancer and Diabetes Treatment Initiatives: Fact.MR

Award winning market research company Fact.MR is currently pursuing a study on the global subcutaneous biologics market. Growth prospects for 2021 and beyond appear significant, with healthcare providers resuming R&D projects which has suffered a setback amidst the coronavirus pandemic crisis.

As per Fact.MR’s analysis, the subcutaneous biologics market stands to gain the maximum from cancer and diabetes drugs development. While the International Diabetes Federation estimates that the number of diabetics shall increase to 578 million people by 2030 from the existing 463 million, the number of cancer patients are likely to rise by over 80% across low-income countries; and 40% in high-income countries (WHO).

Consequently, government entities are fast tracking drug candidate approvals so as to offset this increasing burden. In June 2020, for instance, the US Food & Drug Administration approved Genentech Inc.’s Phesgo (pertuzumab, trastuzumab and hyaluronidase- zzxf) for injection under the skin to treat adult patients with HER-2 positive breast cancer. Likewise, in March 2020, Celltrion announced the launch of its subcutaneous Remsima (infliximab) formulation, which is the only subcutaneous formulation of the Remicade biosimilar for treating rheumatoid arthritis patients.

Request Brochure at

The global subcutaneous biologics market is classified based indication, delivery system, distribution channel and region.

Based on the indication, the subcutaneous biologics market is segmented into the following:

  • Cancer
  • Crohn’s disease
  • Cardiovascular disorders
  • Diabetes
  • Multiple sclerosis
  • Psoriasis
  • Rheumatoid Arthritis
  • Metabolic disorders
  • Growth hormone deficiency
  • Others

Based on the delivery system, the subcutaneous biologics market is segmented into the following:

  • Syringe
  • Wearable injector
  • Automatic injector
  • Implants
  • Pen injectors
  • Others

Based on the distribution channel, the subcutaneous biologics market is segmented into the following:

  • Hospital pharmacies
  • Retail pharmacies
  • Drug stores
  • Online pharmacies

Subcutaneous Biologics Market- Prominent Drivers

  • Expanding geriatric population pool and subsequent increase in chronic ailments prevalence to drive future subcutaneous biologics sales
  • Key manufacturers are targeting the Asia-Pacific region for future growth, attributed to an exponential population surge
  • Increased research & development funding along with favorable government policies are accelerating subcutaneous biologics research

Subcutaneous Biologics Market- Key Restraints

  • Documented allergic reactions post-biologics consumption is likely to hinder uptake across key regions
  • Prolonged waiting durations with respect to regulatory approvals is expected to slow subcutaneous biologics adoption

Discover more about the subcutaneous biologics market on –

Key Takeaways from Fact.MR’s Subcutaneous Biologics Market Study

  • Subcutaneous biologic drug development for cancers is expected to acquire massive momentum
  • By delivery system, pen injectors are likely to become the preferred administration route
  • Rising popularity of home diagnostics compelling high subcutaneous biologics sales through retail pharmacies
  • Increasing cancer and diabetes incidence stimulating subcutaneous biologics development across the US
  • UK to experience high growth amid increasing research funding for psoriasis treatment
  • Conducive government policies to promote biologics and biosimilars development to heighten Germany and France’s growth prospects
  • India and China to collectively cement their dominance across the Asian market

Competitive Landscape

Prominent subcutaneous biologics market players profiled by Fact.MR include Abbott Laboratories, Pfizer Inc., Genentech Inc., Novartis AG, Biogen Idec, AbbVie Inc, F. Hoffmann-La Roche AG, Genmab A/S, Bristol-Myers Squibb, Eisai Inc., Takeda Pharmaceuticals Ltd., Alnylam Pharmaceuticals, Bayer AG, GlaxoSmithKline, Sanofi SA and Boston Pharmaceuticals among others.

The aforementioned market players rely on regulatory approvals of their product lines in order to enhance their penetration into the market. In March 2021, Genentech’s Actemra became the first biologic therapy approved by the US FDA for slowing the rate of decline in pulmonary function in adults suffering from systemic sclerosis-associated interstitial lung disease.

Likewise, in August 2020, the FDA approved Genmab A/S’s Kesimpta® (ofatumumab) injection for subcutaneous use to treat relapsing forms of multiple sclerosis (RMS) in adults, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. Kesimpta is the first B-cell therapy which is suitable for self-administration.

More Insights on the Subcutaneous Biologics Market

Fact.MR, in its new offering, brings to fore an unbiased analysis of the global subcutaneous biologics market, presenting historical demand data (2016-2020) and forecast statistics for the period, 2021-2031. The study divulges compelling insights on the market based on indication (cancer, Crohn’s disease, cardiovascular disorders, diabetes, multiple sclerosis, psoriasis, rheumatoid arthritis, metabolic disorders, growth hormone deficiency and others), delivery system (syringe, wearable injector, automatic injector, implants, pen injectors and others) and distribution channel (hospital pharmacies, retail pharmacies, online pharmacies and drug stores) across seven major regions (North America, Latin America, Europe, South Asia, East Asia, Oceania and Middle East & Africa).

Explore Fact.MR’s Coverage on the Healthcare Domain: 

Leukocyte Count Testing Market – According to the latest research by Fact.MR, the leukocyte count testing market is set to witness exponential growth with over 7%-8% CAGR during 2021-2031. Increasing bacterial infection with the growing adoption of point of care devices will witness a promising growth outlook for leukocyte count testing in the long run.

At-Home Celiac Testing Market – According to the Latest Research by the Fact.MR The Celiac Testing market is set to gain growth in the forecast period 2021-2031 at a CAGR of 8.0%. The Reason for the growth is The increase in prevalence of Celiac disease globally.

Polysaccharide Hemostatic System Market – According to the latest research by Fact.MR, Polysaccharide Hemostatic System market is set to witness a XX% growth during the year 2021-2031.

About Fact.MR

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates

Visit Our Website: